CoChat

What Is “Metabolically Healthy Obesity”?: From Epidemiology to Pathophysiological Insights

Després, Jean-Pierre · 2012 · The Journal of Clinical Endocrinology & Metabolism
Cited by 55

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Although it is well recognized that obesity is a health hazard, its heterogeneity has remained a challenge in clinical practice (1). For instance, whereas there is a clear link between obesity and complications such as dyslipidemia, hypertension, and type 2 diabetes, not every obese patient is characterized by these risk factors. Obesity is defined by an excess of body fat associated with increased health risk, and its diagnosis is generally made on the basis of a body mass index (BMI) greater than 30 kg/m2. The study by Hamer and Stamatakis (2) provides additional evidence that one can find individuals with a diagnosis of clinical obesity defined on the basis of their BMI but without the expected cardiovascular disease (CVD) risk factors. In their study, this subgroup of participants represented 5.2% of the overall cohort of 22,203 individuals who were followed for an average of 7 yr. Over this period, there were 604 CVD deaths and 1868 all-cause deaths. Results of this well-conducted prospective study are pretty straightforward: obese individuals not characterized by risk factors were not found to be at increased CVD, and their total mortality risk was comparable to that of metabolically healthy nonobese participants. Thus, in the absence of CVD risk factors, obesity by itself does not appear to be a major risk factor for CVD and related mortality. On the other hand, metabolically unhealthy nonobese subjects were at increased risk for CVD and all-cause deaths. Results of this prospective study are based on a large sample size with a considerable number of deaths. The observations are therefore robust. However, one of the key remaining questions to be answered is the following: who are these individuals who are obese from a BMI standpoint but who appear to be able to “get away” with their excess of body weight/fat and remain metabolically healthy? First, the proportion of obese individuals who are nevertheless metabolically healthy is not trivial because they represented about 22% of the sample of obese participants examined in this cohort. Thus, we need to identify them in clinical practice because they do not share the risk burden of their peers. On the other hand, there was also a fairly large subgroup of presumably nonobese individuals (about 25% of participants with a BMI <30 kg/m2) who were characterized by metabolic risk factors and who were at increased risk for CVD and total mortality. Thus, the present study provides further evidence that the BMI is not the optimal anthropometric variable to estimate the health hazards of obesity. As acknowledged by the authors, this large epidemiological study could not afford sophisticated and costly imaging measurements of visceral adiposity and of ectopic fat depots. There is now emerging evidence from several computed tomography and magnetic resonance imaging studies that excess visceral adiposity and liver fat content are two key drivers of cardiometabolic risk associated with a given level of total body fat (3–6). In the present study, it is therefore very likely that obese individuals who were metabolically healthy had low levels of visceral adipose tissue and of liver fat, whereas nonobese metabolically unhealthy individuals probably had increased levels of visceral/ectopic fat. Cross-sectional analyses of large metabolic/imaging studies have revealed considerable individual variation in visceral adiposity/liver fat at any BMI level (3–6). Upcoming prospective analyses of these metabolic imaging studies are currently under way, and they should eventually shed some light on the important role played by body fat distribution, particularly by visceral adipose tissue/liver fat and by other ectopic fat depots in explaining this remarkable metabolic heterogeneity of obesity (7–9). In their discussion, Hamer and Stamatakis (2) state that their “findings suggest that metabolic risk factors are more important predictors of CVD than overall adiposity” and that “this is consistent with recent data from a collaborative analysis of 58 prospective studies”. Although this statement is correct from an epidemiological standpoint, they should be reminded that in the Emerging Risk Factors Collaboration study, adiposity indices were powerful correlates of deteriorated levels of intermediate risk factors (10). These strong associations between body fatness variables and risk factors are not trivial and have important public health/clinical implications: should we therefore let people become obese and rather treat their hypertension, dyslipidemia, and diabetes downstream with pharmacological agents, or should we work upstream to target the driving force behind these complications? Whereas Hamer and Stamatakis (2) appropriately address later in their discussion the importance of early intervention with diet and exercise, we need to reflect on the fact that our current health care system is unfortunately better designed to promote pharmacotherapy of risk factors rather than to

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2012-2081

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 55

Metadata

Authors
Després, J.-P.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-07-01
Volume
97
Issue
7
Pages
2283-2285
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2090963890
Cited by
55
References
5
FWCI
5.52
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.